iRhythm Holdings, Inc. (IRTC)

Over the past six months, iRhythm Holdings, Inc. stock has decreased by approximately 31.55%. Key events impacting the stock include strong Q4 2025 and Q1 2026 earnings reports, analyst coverage with a consensus rating of 'Moderate Buy' and a potential upside of about 60.3%, ongoing DOJ related headline risk, and collaboration with the FDA regarding its next-generation AI algorithm.

iRhythm Holdings, Inc. experiences normal seasonality in its business operations. The company anticipates higher adjusted operating expenses in the earlier half of the year due to corporate activities and payroll expenses. Free cash flow is typically more heavily weighted in the second half of the year due to normal operating seasonality. Revenue is also consistent with typical seasonality. Despite seasonality, the company has reported sustained volume demand across its customer base.

iRhythm Holdings, Inc. is a digital healthcare company specializing in device-based technology for ambulatory cardiac monitoring services. The company designs, develops, and commercializes solutions to diagnose arrhythmias more quickly and efficiently than traditional methods. iRhythm's major products are part of the Zio family of solutions, which include the Zio Monitor System, Zio XT System, Zio AT System, Zio ECG Utilization Software System (ZEUS System), and Zio Watch. These systems combine a wire-free, patch-based wearable biosensor with cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

iRhythm Holdings, Inc. is headquartered in San Francisco, California, and has corporate, clinical operations, and research and development facilities there. It operates a manufacturing facility in Orange County, California, and has clinical operations facilities in Deerfield, Illinois, and Houston, Texas. Internationally, iRhythm has a presence in the United Kingdom and the Philippines. The deep-learned algorithm used in its monitoring service is available in the United States, European Union, Switzerland, and the United Kingdom.

In the past year, iRhythm Holdings has focused on reinforcing the clinical value and superiority of its Zio ambulatory ECG devices. The company presented new real-world retrospective analyses at the Heart Rhythm Society's annual meetings in April 2026 and 2025, and presented data on arrhythmias detected by long-term ambulatory ECG monitoring in patients with diabetes, chronic kidney disease, and obesity at the American College of Cardiology in March 2026. The company has been working collaboratively with the FDA to advance an enhanced next-generation AI algorithm for clearance.

iRhythm Holdings, Inc. has 334 institutional owners and shareholders holding a total of 35,160,568 shares, with major institutional owners including Vanguard Group Inc. and BlackRock, Inc. Individual insiders own approximately 0.993% of the company's shares, and insider selling has been observed in the past three months.